Skip to main content
SpringerLink
Log in

New Oral Anticoagulants

  • Chapter
  • First Online:
Handbook of Oral Anticoagulation

  • 1381 Accesses

Abstract

Anticoagulation can be achieved by inhibition of the various coagulation factors. For example, as discussed in the preceding chapters, warfarin reduces the level of functional vitamin K-dependent factors II (prothrombin), VII, IX, and X by preventing their γ-carboxylation. Novel oral anticoagulant development has focused on the synthesis of selective inhibitors of coagulation factors, preferably acting independently of cofactors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451:914-918.

    Google Scholar 

  2. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028-1040.

    Google Scholar 

  3. Wallentin L, Wilcox RG, Weaver WD, et al; ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362:789-797.

    Google Scholar 

  4. Fiessinger JN, Huisman MV, Davidson BL, et al; THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005;293:681-689.

    Google Scholar 

  5. Agnelli G, Eriksson BI, Cohen AT, et al; on behalf of the EXTEND Study Group. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thromb Res. 2009;123:488-497.

    Google Scholar 

  6. Wienen W, Stassen JM, Priepke H, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007;98:333-338.

    Google Scholar 

  7. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47-59.

    Google Scholar 

  8. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303.

    Google Scholar 

  9. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2008;28:380-386.

    Google Scholar 

  10. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BIST RO I. J Thromb Haemost. 2004;2:1573-1580.

    Google Scholar 

  11. Eriksson BI, Dahl OE, Büller HR, et al; BIST RO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BIST RO II randomized trial. J Thromb Haemost. 2005;3:103-111.

    Google Scholar 

  12. Eriksson BI, Dahl OE, Rosencher N, et al; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-2185.

    Google Scholar 

  13. Eriksson BI, Dahl OE, Huo MH, et al; RE-NOV ATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOV ATE II *). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721-729.

    Google Scholar 

  14. RE-MOBILI ZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty.2009;24:1-9.

    Google Scholar 

  15. Eriksson BI, Dahl OE, Rosencher N, et al; RE-NOV ATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-956.

    Google Scholar 

  16. Colwell CW, Spiro TE. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin Orthop Relat Res. 1995;319:215.

    Google Scholar 

  17. Schulman S, Kearon C, Kakkar AK, et al; RE-COVE R Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.

    Google Scholar 

  18. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PET RO Study). Am J Cardiol. 2007;100:1419-1426.

    Google Scholar 

  19. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1131.

    Google Scholar 

  20. Oldgren J, Budaj A, Granger CB, et al; RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781-2789.

    Google Scholar 

  21. Schulman S, Baanstra D, Eriksson H, et al. Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism. ISTH 2011; July 25, 2011; Kyoto, Japan. Abstract O-MO -037.

    Google Scholar 

  22. Schulman S, Eriksson H, Goldhaber SZ, et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. ISTH 2011; July 28, 2011; Kyoto, Japan. Abstract O-TH -033.

    Google Scholar 

  23. Turpie AG, Bauer KA, Davidson BL, et al; EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101:68-76.

    Google Scholar 

  24. Connolly SJ, Ezekowitz MD, Diaz R, Hohnloser SH, Dorian P. A phase 2, randomized, parallel group, dose-finding, multicenter, multinational study of the safety, tolerability and pilot efficacy of three blinded doses of the oral factor Xa inhibitor betrixaban compared with open-label dose-adjusted warfarin in patients with non-valvular atrial fibrillation (EXPLO RE-Xa). Presentation at the American College of Cardiology (ACC) 59th Annual Scientific Session; Atlanta, GA; 2010.

    Google Scholar 

  25. Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010;104:642-649.

    Google Scholar 

  26. Agnelli G, Haas S, Ginsberg JS, et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost. 2007;5:746-753.

    Google Scholar 

  27. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2009;374:787-795.

    Google Scholar 

  28. Kakar P, Watson T, Lip GYH. Drug evaluation: Rivaroxaban, an oral, direct inhibitor of activated Factor X. Curr Opin Investig Drugs. 2007;8:256-265.

    Google Scholar 

  29. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873-880.

    Google Scholar 

  30. Gruber A, Marzec UM, Buetehorn U, Hanson S, Perzborn E. Potential of activated prothrombin complex concentrate and activated Factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood (ASH Annual Meeting Abstracts). 2008;112:1307:abstract 3825.

    Google Scholar 

  31. Perzborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. J Thromb Haemost. 2009;7:379:abstract PP -MO -183.

    Google Scholar 

  32. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10:61-75.

    Google Scholar 

  33. Eriksson BI, Borris LC, Dahl OE, et al; ODI Xa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374-2381.

    Google Scholar 

  34. Eriksson BI, Borris L, Dahl OE, et al; ODI Xa-HIP Study Investigators. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4:121-128.

    Google Scholar 

  35. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res. 2007;120:685-693.

    Google Scholar 

  36. Turpie AG, Fisher WD, Bauer KA, et al; OdiXa-Knee Study Group. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3:2479-2486.

    Google Scholar 

  37. Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost. 2007;97:931-937.

    Google Scholar 

  38. Eriksson BI, Borris LC, Friedman RJ, et al; RECO RD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.

    Google Scholar 

  39. Lassen MR, Ageno W, Borris LC, et al; RECO RD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786.

    Google Scholar 

  40. Kakkar AK, Brenner B, Dahl OE, et al; RECO RD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-39.

    Google Scholar 

  41. Turpie AG, Lassen MR, Davidson BL, et al; RECO RD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECO RD4): a randomised trial. Lancet. 2009;9676:1673-1680.

    Google Scholar 

  42. Cohen AT, Spiro TE, Buller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011;31:407-416.

    Google Scholar 

  43. Agnelli G, Gallus A, Goldhaber SZ, et al; ODI Xa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODI Xa- DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation. 2007;116:180-187.

    Google Scholar 

  44. Buller HR, Lensing AW, Prins MH, et al; EINSTEIN-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN- DVT Dose-Ranging Study. Blood. 2008;112:2242-2247.

    Google Scholar 

  45. The EINSTEIN -PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-1297.

    Google Scholar 

  46. Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther. 2011;9:841-844.

    Google Scholar 

  47. EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-2510.

    Google Scholar 

  48. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.

    Google Scholar 

  49. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.

    Google Scholar 

  50. Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation. Circ J. 2012 Jun 5. [Epub ahead of print].

    Google Scholar 

  51. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820-829.

    Google Scholar 

  52. Mega JL, Braunwald E, Mohanavelu S, et al; ATLAS ACS-TIMI 46 study group.Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374:29-38.

    Google Scholar 

  53. Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs. 2008;9:1020-1033.

    Google Scholar 

  54. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;36:594-604.

    Google Scholar 

  55. Lassen MR, Raskob GE, Gallus A, et al; ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807-815.

    Google Scholar 

  56. Lassen MR, Gallus A, Raskob GE, et al; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487-2498.

    Google Scholar 

  57. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.

    Google Scholar 

  58. Connolly SJ, Eikelboom J, Joyner C, et al; AVE RROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.

    Google Scholar 

  59. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167-2177.

    Google Scholar 

  60. APPRAISE Steering Committee and Investigators; Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877-2885.

    Google Scholar 

  61. APPRAISE-2 Investigators; Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699-708

    Google Scholar 

  62. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5:2368-2375.

    Google Scholar 

  63. Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10:807-814.

    Google Scholar 

  64. Botticelli Investigators, Writing Committee; Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6:1313-1318.

    Google Scholar 

  65. AMPLIFY-EXT Investigators; Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708. Fukuda T, Matsumoto C, Honda Y, Sugiyama N, Morishima Y, Shibano T. Antithrombotic properties of DU-176b, a novel, potent and orally active direct Factor Xa inhibitor in rat models of arterial and venous thrombosis: comparison with fondaparinux, an antithrombin dependent Factor Xa inhibitor. ASH Annual Meeting Abstracts. 2004;104:1852.

    Google Scholar 

  66. Fukuda T, Matsumoto C, Honda Y, Sugiyama N, Morishima Y, Shibano T. Antithrombotic properties of DU-176b, a novel, potent and orally active direct Factor Xa inhibitor in rat models of arterial and venous thrombosis: comparison with fondaparinux, an antithrombin dependent Factor Xa inhibitor. ASH Annual Meeting Abstracts. 2004;104:1852.

    Google Scholar 

  67. Furugohri T, Honda Y, Matsumoto C, Isobe K, Sugiyama N, Morishima Y, Shibano T. Antithrombotic and hemorrhagic effects of DU-176b, a novel, potent and orally active direct Factor Xa inhibitor: a wider safety margin compared to heparins and warfarin. ASH Annual Meeting Abstracts. 2004;104:1851.

    Google Scholar 

  68. Morishima Y, Furugohri T, Honda Y, et al. Antithrombotic properties of DU-176b, a novel orally active Factor Xa inhibitor: inhibition of both arterial and venous thrombosis, and combination effects with other antithrombotic agents. J Thromb Haemost. 2005;3:abstract PO 511.

    Google Scholar 

  69. Zafar MU, Gaztanga J, Velez M, et al. A phase-I study to assess the antithrombotic properties of DU-176b: an orally active direct Factor-Xa inhibitor. J Am Coll Cardiol. 2006;47:288A.

    Google Scholar 

  70. Daiichi Sankyo Inc. Global study to assess the safety and effectiveness of DU-176b vs standard practice of dosing with warfarin in patients with atrial fibrillation (EngageAFTIMI 48) [ClinicalTrials.gov identifier NCT 00781391]. US National Institutes of Health, ClinicalTrials.gov. Available at: www.clinicaltrials.gov. [Accessed June 13, 2013].

Download references

Author information

Authors and Affiliations

  1. University of Birmingham, Birmingham, UK

    Eduard Shantsila, Stavros Apostolakis & Gregory YH Lip

Authors
  1. Eduard Shantsila
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stavros Apostolakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory YH Lip
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory YH Lip .

Editor information

Editors and Affiliations

  1. University of Birmingham, Birmingham B18 7QH, United Kingdom

    Gregory YH Lip

  2. Centre for Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom

    Eduard Shantsila

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Healthcare

About this chapter

Cite this chapter

Shantsila, E., Apostolakis, S., Lip, G.Y. (2013). New Oral Anticoagulants. In: Lip, G., Shantsila, E. (eds) Handbook of Oral Anticoagulation. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-96-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-96-8_5

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-58-6

  • Online ISBN: 978-1-908517-96-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation